DRD2 and Delusion: In addition to an overall effect on symptoms using the broadest symptom measure available in each study and an overall effect on positive symptom scales, we found significant effects in our bootstrap models of opioid antagonists on both hallucinations and delusions, suggesting antipsychotic activity for a class of compounds that are not dopamine 2 receptor (D2R) antagonists.